- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-SOX2 monoclonal antibody
Pre-made anti-SOX2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to SOX2/SOX2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T00724-Ab-1/ GM-Tg-hg-T00724-Ab-2 | Anti-Human SOX2 monoclonal antibody | Human |
| GM-Tg-rg-T00724-Ab-1/ GM-Tg-rg-T00724-Ab-2 | Anti-Rat SOX2 monoclonal antibody | Rat |
| GM-Tg-mg-T00724-Ab-1/ GM-Tg-mg-T00724-Ab-2 | Anti-Mouse SOX2 monoclonal antibody | Mouse |
| GM-Tg-cynog-T00724-Ab-1/ GM-Tg-cynog-T00724-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SOX2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T00724-Ab-1/ GM-Tg-felg-T00724-Ab-2 | Anti-Feline SOX2 monoclonal antibody | Feline |
| GM-Tg-cang-T00724-Ab-1/ GM-Tg-cang-T00724-Ab-2 | Anti-Canine SOX2 monoclonal antibody | Canine |
| GM-Tg-bovg-T00724-Ab-1/ GM-Tg-bovg-T00724-Ab-2 | Anti-Bovine SOX2 monoclonal antibody | Bovine |
| GM-Tg-equg-T00724-Ab-1/ GM-Tg-equg-T00724-Ab-2 | Anti-Equine SOX2 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T00724-Ab-1/ GM-Tg-hg-T00724-Ab-2; GM-Tg-rg-T00724-Ab-1/ GM-Tg-rg-T00724-Ab-2; GM-Tg-mg-T00724-Ab-1/ GM-Tg-mg-T00724-Ab-2; GM-Tg-cynog-T00724-Ab-1/ GM-Tg-cynog-T00724-Ab-2; GM-Tg-felg-T00724-Ab-1/ GM-Tg-felg-T00724-Ab-2; GM-Tg-cang-T00724-Ab-1/ GM-Tg-cang-T00724-Ab-2; GM-Tg-bovg-T00724-Ab-1/ GM-Tg-bovg-T00724-Ab-2; GM-Tg-equg-T00724-Ab-1/ GM-Tg-equg-T00724-Ab-2 |
| Products Name | Anti-SOX2 monoclonal antibody |
| Format | mab |
| Target Name | SOX2 |
| Protein Sub-location | Introcelluar Protein |
| Category of antibody | Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
| Tag | Fc |
| Products description | Pre-made anti-SOX2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-T00724-Ag-1 | Recombinant multi-species SOX2/ ANOP3/ MCOPS3 protein |
| ORF Viral Vector | vGMLV000264 | human SOX2 Lentivirus particle |
| ORF Viral Vector | pGMAP000433 | Human SOX2 Adenovirus plasmid |
| ORF Viral Vector | pGMLV000263 | human SOX2 Lentivirus plasmid |
| ORF Viral Vector | vGMLV000263 | human SOX2 Lentivirus particle |
| ORF Viral Vector | vGMAP000433 | Human SOX2 Adenovirus particle |
| ORF Viral Vector | pGMLV000264 | human SOX2 Lentivirus plasmid |
| ORF Viral Vector | pGMAD000053 | rat Sox2 Adenovirus plasmid |
| ORF Viral Vector | pGMLPm002981 | mouse Sox2 Lentivirus plasmid |
| ORF Viral Vector | vGMAD000053 | rat Sox2 Adenovirus particle |
| ORF Viral Vector | vGMLPm002981 | mouse Sox2 Lentivirus particle |
Target information
| Target ID | GM-T00724 |
| Target Name | SOX2 |
| Gene ID | 6657,20674,499593,707039,488092,100379629,784383,100146979 |
| Gene Symbol and Synonyms | ANOP3,lcc,MCOPS3,RGD1565646,Sox-2,SOX2,ysb |
| Uniprot Accession | P48431 |
| Uniprot Entry Name | SOX2_HUMAN |
| Protein Sub-location | Introcelluar Protein |
| Category | Therapeutics Target |
| Disease | Lung Cancer |
| Gene Ensembl | ENSG00000181449 |
| Target Classification | N/A |
The target: SOX2, gene name: SOX2, also named as ANOP3, MCOPS3. This intronless gene encodes a member of the SRY-related HMG-box (SOX) family of transcription factors involved in the regulation of embryonic development and in the determination of cell fate. The product of this gene is required for stem-cell maintenance in the central nervous system, and also regulates gene expression in the stomach. Mutations in this gene have been associated with optic nerve hypoplasia and with syndromic microphthalmia, a severe form of structural eye malformation. This gene lies within an intron of another gene called SOX2 overlapping transcript (SOX2OT). [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
